Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($1.56), $0.51 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.38 million versus the consensus estimate of $5.54 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.